GSK bullish on RSV vaccine battle against Pfizer, ships first Arexvy dose

GSK is bull­ish about the mar­ket prospects for its RSV vac­cine Arexvy in old­er adults.

The Big Phar­ma has al­ready shipped its first dos­es to US dis­tri­b­u­tion cen­ters, ini­ti­at­ed its dis­ease aware­ness cam­paign and set plans to use its ex­ist­ing in­ter­na­tion­al field force.

The multi­bil­lion-dol­lar RSV vac­cine launch race was a hot top­ic at GSK’s sec­ond-quar­ter earn­ings call. GSK se­cured FDA ap­proval for Arexvy in May, with Pfiz­er lock­ing in FDA sup­port for its own RSV vac­cine Abrys­vo a few weeks lat­er. Fol­low­ing the Eu­ro­pean Com­mis­sion’s Arexvy go-ahead in June 2023, GSK is build­ing to­ward a third-quar­ter launch in Eu­rope.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN